The Clinical Trials Toolkit is an interactive colour-coded routemap* to help navigate through the legal and good practice arrangements surrounding setting up and managing a Clinical Trial of an Investigational Medicinal Product (CTIMP). The routemap distinguishes between legal and good practice requirements, and indicates which aspects of these are relevant to wider clinical research in general. It includes an overview of trial practices, along with more detailed information available at ‘stations’ along the route.
*Mobile users will be able to access the stations from the list shown at the bottom of the screen
Download a copy of the Clinical Trials Toolkit routemap (pdf, 221.33 KB). Also available is the Clinical Trials Toolkit website leaflet (pdf, 62.64 KB) which details the benefits and features of the website.
Getting Started with the Routemap
The Clinical Trials Toolkit is designed to help understand the requirements of the UK Medicines for Human Use (Clinical Trials) Regulations, which implemented the EU Clinical Trials Directive (2001/20/EC) in the UK.
Users should note the following features in the routemap;
- The positioning of the stations (from left to right) gives an indication of the critical path and process flow.
- Activities that may be undertaken in parallel are indicated.
- By clicking on a station, you will be taken to a description of the process and a list of relevant resources and/or related stations.
- Station symbols can either be closed (small hole) which apply to trials covered by the CT Regulations, or open (large hole) which apply to all trials.
- Legal requirements are red. Where an open station includes statutory requirements for CTIMPs, (even if the requirement is not a general legal requirement for non-CTIMPs) the station, by default, will be identified in red.
- Good Practice requirements are blue. In many cases, good practice requirements may be considered mandatory even if the requirement does not have statutory force (e.g. by Funders or the NHS).
- Standard processes are black.
Before using the routemap, take time to think about your trial and its setting. Consider the following:
- The research question
The nature of the intervention will determine whether the trial is subject to the regulations. The routemap contains advice on management arrangements for different kinds of trial.
- Where you are in the trial process
The key stages of the trial process are identified as ‘stations’. By selecting a station you will find one or more ‘resources’. The resources provide advice and links to other useful websites and resources.
- The expertise of your trials team and organisation
Some resources within the Toolkit address the needs of trialists, whilst others are of particular interest to those involved with R&D management. Using the resources may reveal gaps in the capacity of your trials team or organisation to support trials to the required standards. Organisations vary considerably in how they approach their responsibilities to support high quality clinical trials.
- The importance of Patient and Public Involvement
Consider how best to involve members of the public in your work. See INVOLVE’s briefing notes for researchers.
PPI guidance for Chief Investigators of UK surgical trials has been developed from the 'Patient and public involvement Intervention to enhance Recruitment and Retention in Surgical Trials' (PIRRIST) project.
Trials that began before 1 May 2004
The Medicines for Human Use (Clinical Trials) Regulations came into force on 1 May 2004. Any trials initiated before this date (i.e. trials which had a Clinical Trial Certificate (CTC) or Clinical Trial Exemption (CTX) or which had been notified under the Doctors and Dentists Exemption (DDX) scheme) and that were ongoing after 1 May 2004 were required to ensure that systems were put in place to comply with these regulations.
The MRC/DH Joint Project produced a Checklist for Ongoing Trials in 2004 which helped sponsors identify any immediate actions to be taken in relation to their trials. The MHRA also published advice on amendments or end of trial declarations for clinical trials that were originally CTX/DDX/CTC applications.